{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:39:06Z","timestamp":1792535946282,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01739-6","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:05:59Z","timestamp":1792490759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strengthening Signal Detection by Proactive Adverse Event Case Identification in Electronic Health Records Using a Text-Mining Tool"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6521-9592","authenticated-orcid":false,"given":"Gabri\u00eblla","family":"von Kreijfelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00ebtte","family":"Zwaveling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette A.","family":"van Lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes E.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes C.","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"10","key":"1739_CR1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/17512433.2018.1526676","volume":"11","author":"A Farca\u015f","year":"2018","unstructured":"Farca\u015f A, M\u0103h\u0103lean A, Bulik NB, Leucuta D, Mogo\u0219an C. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017. Expert Rev Clin Pharmacol. 2018;11(10):1045\u201351. https:\/\/doi.org\/10.1080\/17512433.2018.1526676.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"1739_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-014-0240-1","volume":"37","author":"AC Pacurariu","year":"2014","unstructured":"Pacurariu AC, Coloma PM, van Haren A, Genov G, Sturkenboom MC, Straus SM. A description of signals during the first 18 months of the EMA Pharmacovigilance Risk Assessment Committee. Drug Saf. 2014;37(12):1059\u201366. https:\/\/doi.org\/10.1007\/s40264-014-0240-1.","journal-title":"Drug Saf"},{"issue":"3","key":"1739_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/pds.3395","volume":"22","author":"J Lester","year":"2013","unstructured":"Lester J, Neyarapally GA, Lipowski E, Graham CF, Hall M, Dal Pan G. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013;22(3):302\u20135. https:\/\/doi.org\/10.1002\/pds.3395.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1739_CR4","unstructured":"European Medicines Agency. Safety signal glossary: regulatory terms. https:\/\/www.ema.europa.eu\/en\/glossary-terms\/safety-signal. Accessed 14 Jan 2026."},{"issue":"5","key":"1739_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003.","journal-title":"Drug Saf"},{"issue":"4","key":"1739_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzae109","volume":"36","author":"M Lavall\u00e9e","year":"2024","unstructured":"Lavall\u00e9e M, Corbin S, Pradhan P, Guefack LB, Thibault M, M\u00e9thot J, et al. Underreporting of adverse events to health authorities by healthcare professionals: a red flag-raising descriptive study. Int J Qual Health Care. 2024;36(4):mzae109. https:\/\/doi.org\/10.1093\/intqhc\/mzae109.","journal-title":"Int J Qual Health Care"},{"issue":"4","key":"1739_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40272-020-00405-3","volume":"22","author":"ATM Dittrich","year":"2020","unstructured":"Dittrich ATM, Draaisma JMT, van Puijenbroek EP, Loo D. Analysis of reporting adverse drug reactions in paediatric patients in a university hospital in the Netherlands. Paediatr Drugs. 2020;22(4):425\u201332. https:\/\/doi.org\/10.1007\/s40272-020-00405-3.","journal-title":"Paediatr Drugs"},{"issue":"5","key":"1739_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00228-015-1839-6","volume":"71","author":"SA Karlsson","year":"2015","unstructured":"Karlsson SA, Jacobsson I, Boman MD, Hakkarainen KM, L\u00f6vborg H, H\u00e4gg S, et al. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses\u2019 reporting. Eur J Clin Pharmacol. 2015;71(5):631\u20136. https:\/\/doi.org\/10.1007\/s00228-015-1839-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1739_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40264-023-01302-7","volume":"46","author":"P Garc\u00eda-Abeijon","year":"2023","unstructured":"Garc\u00eda-Abeijon P, Costa C, Taracido M, Herdeiro MT, Torre C, Figueiras A. Factors associated with underreporting of adverse drug reactions by health care professionals: a systematic review update. Drug Saf. 2023;46(7):625\u201336. https:\/\/doi.org\/10.1007\/s40264-023-01302-7.","journal-title":"Drug Saf"},{"issue":"1","key":"1739_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","volume":"32","author":"E Lopez-Gonzalez","year":"2009","unstructured":"Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19\u201331. https:\/\/doi.org\/10.2165\/00002018-200932010-00002.","journal-title":"Drug Saf"},{"issue":"2","key":"1739_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/pds.3687","volume":"24","author":"L Rolfes","year":"2015","unstructured":"Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug reaction reports of patients and healthcare professionals: differences in reported information. Pharmacoepidemiol Drug Saf. 2015;24(2):152\u20138. https:\/\/doi.org\/10.1002\/pds.3687.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1739_CR12","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/bcp.13576","volume":"84","author":"L Rolfes","year":"2018","unstructured":"Rolfes L, van Hunsel F, Caster O, Taavola H, Taxis K, van Puijenbroek E. Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. Br J Clin Pharmacol. 2018;84(7):1514\u201324. https:\/\/doi.org\/10.1111\/bcp.13576.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1739_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40264-017-0530-5","volume":"40","author":"L Rolfes","year":"2017","unstructured":"Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis. Drug Saf. 2017;40(7):607\u201314. https:\/\/doi.org\/10.1007\/s40264-017-0530-5.","journal-title":"Drug Saf"},{"key":"1739_CR14","doi-asserted-by":"publisher","first-page":"1644680","DOI":"10.3389\/fdsfr.2025.1644680","volume":"5","author":"F van Hunsel","year":"2025","unstructured":"van Hunsel F, Kant A. A national pharmacovigilance centre perspective on pandemic preparedness: lessons learned from the COVID-19 pandemic. Front Drug Saf Regul. 2025;5:1644680. https:\/\/doi.org\/10.3389\/fdsfr.2025.1644680.","journal-title":"Front Drug Saf Regul."},{"issue":"1","key":"1739_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-024-02070-2","volume":"48","author":"H Abedian Kalkhoran","year":"2024","unstructured":"Abedian Kalkhoran H, Zwaveling J, van Hunsel F, Kant A. An innovative method to strengthen evidence for potential drug safety signals using electronic health records. J Med Syst. 2024;48(1):51. https:\/\/doi.org\/10.1007\/s10916-024-02070-2.","journal-title":"J Med Syst"},{"key":"1739_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127549","volume":"62","author":"W van der Weg","year":"2025","unstructured":"van der Weg W, von Kreijfelt G, Davidson L, Zwaveling J, Visser LE, van Hunsel F, et al. Strengthening spontaneous reporting-based signal detection during a pandemic with cases from electronic health records using a natural language processing tool. Vaccine. 2025;62:127549. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127549.","journal-title":"Vaccine"},{"key":"1739_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.106536","volume":"142","author":"G von Kreijfelt","year":"2025","unstructured":"von Kreijfelt G, Davidson L, Holtrust YJ, Arends M, Zwaveling J. Severe acute refractory hyperkalaemia associated with liposomal amphotericin B infusion. Eur J Intern Med. 2025;142:106536. https:\/\/doi.org\/10.1016\/j.ejim.2025.106536.","journal-title":"Eur J Intern Med"},{"key":"1739_CR18","unstructured":"Nederlands Huisartsen Genootschap (NHG). NHG clinical practice guidelines. https:\/\/richtlijnen.nhg.org\/. Accessed 12 Oct 2026."},{"key":"1739_CR19","unstructured":"Federatie Medisch Specialisten (FMS). Richtlijnendatabase. https:\/\/richtlijnendatabase.nl\/. Accessed 12 Oct 2026."},{"key":"1739_CR20","unstructured":"European Medicines Agency (EMA). MedDRA important medical event terms list: Version 29.0. 2026. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance\/eudravigilance-system-overview. Accessed 1 Apr 2026."},{"issue":"8","key":"1739_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-023-01325-0","volume":"46","author":"SE Davis","year":"2023","unstructured":"Davis SE, Zabotka L, Desai RJ, Wang SV, Maro JC, Coughlin K, et al. Use of electronic health record data for drug safety signal identification: a scoping review. Drug Saf. 2023;46(8):725\u201342. https:\/\/doi.org\/10.1007\/s40264-023-01325-0.","journal-title":"Drug Saf"},{"issue":"9","key":"1739_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40264-025-01548-3","volume":"48","author":"S Crisafulli","year":"2025","unstructured":"Crisafulli S, Bate A, Brown JS, Candore G, Chandler RE, Hammad TA, et al. Interplay of spontaneous reporting and longitudinal healthcare databases for signal management: position statement from the real-world evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance. Drug Saf. 2025;48(9):959\u201376. https:\/\/doi.org\/10.1007\/s40264-025-01548-3.","journal-title":"Drug Saf"},{"issue":"3","key":"1739_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/amiajnl-2012-000930","volume":"20","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20(3):413\u20139. https:\/\/doi.org\/10.1136\/amiajnl-2012-000930.","journal-title":"J Am Med Inform Assoc"},{"issue":"10","key":"1739_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-015-0314-8","volume":"38","author":"Y Li","year":"2015","unstructured":"Li Y, Ryan PB, Wei Y, Friedman C. A ethod to combine signals from spontaneous reporting systems and observational healthcare data to detect adverse drug reactions. Drug Saf. 2015;38(10):895\u2013908. https:\/\/doi.org\/10.1007\/s40264-015-0314-8.","journal-title":"Drug Saf"},{"key":"1739_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001","volume":"17","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. Eclinicalmed. 2019;17:100188. https:\/\/doi.org\/10.1016\/j.eclinm.2019.10.001.","journal-title":"Eclinicalmed"},{"issue":"7","key":"1739_CR26","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/bcp.13923","volume":"85","author":"ST de Vries","year":"2019","unstructured":"de Vries ST, Denig P, Ekhart C, Burgers JS, Kleefstra N, Mol PGM, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study. Br J Clin Pharmacol. 2019;85(7):1507\u201315. https:\/\/doi.org\/10.1111\/bcp.13923.","journal-title":"Br J Clin Pharmacol"},{"key":"1739_CR27","unstructured":"Batenburg R, Vis E, Hansen J, Van der Velden L. Regionale balans in vraag en aanbod medische specialisten. Utrecht: Nivel; 2019."},{"key":"1739_CR28","unstructured":"Zorggebruik. Medisch specialistische zorg. 2023. https:\/\/www.regiobeeld.nl\/zorggebruik\/medisch-specialistische-zorg. Accessed 29 Apr 2026."},{"key":"1739_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2024.1428831","volume":"4","author":"JV Kim","year":"2024","unstructured":"Kim JV, Davis SE, Matheny ME, Smith JC. Integrating electronic health records with other data sources for postmarket drug safety signal identification: a review. Front Drug Saf Regul. 2024;4:1428831. https:\/\/doi.org\/10.3389\/fdsfr.2024.1428831.","journal-title":"Front Drug Saf Regul"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01739-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01739-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01739-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:02:09Z","timestamp":1792533729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01739-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":29,"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01739-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gabri\u00eblla von Kreijfelt, Juli\u00ebtte Zwaveling, Jette A. van Lint, Loes E. Visser, and Agnes C. Kant have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethical Committee of Leiden, The Hague and Delft exempted ethical approval because this study was not subject to the Dutch Medical Research Involving Human Subjects Act (WMO),\u00a0reference nWMO\u2010D4\u20102022\u2010014. Permission for this study was granted by the Board of Directors of Leiden University Medical Center and Haga Hospital.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data underlying this study are not publicly available to safeguard patient privacy. Requests for access to the data may be directed to the corresponding author.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No custom code was developed for this study. EHR-AE searches were performed using the commercial data collector tool CTcue (IQVIA Solutions BV, Amsterdam, the Netherlands). Search queries used in the study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GK, JZ, LEV and AK contributed to the conceptualisation and design of the study. GK and JAL performed the data collection. GK performed the data analysis. All authors contributed to data interpretation. GK drafted the manuscript. All authors contributed to critical review. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}